Work

Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN)

Year: 2023

Type: article

Source: Journal of the American Society of Nephrology

DOI: 10.1681/asn.20233411s1972c

Authors: Brad H. Rovin, Richard Furie, Ana Malvar, Cynthia Aranow, José M. Pego-Reigosa, Elena Zakharova, Andreas Schwarting, Angela R. Jones-Leone, Jennifer A. Gilbride, Beulah Ji, David A. Roth, Paula S. Curtis, André van Maurik

Institutions: The Ohio State University Wexner Medical Center, Hofstra University, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Hospital Fernández, Feinstein Institute for Medical Research, Botkin Hospital, Johannes Gutenberg University Mainz, GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom)

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4397042275

FWCI:

Cites:

Cited by:

Related to: 10